Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

BACKGROUND: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. METHODS: We reviewed the medical records o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Urol
Auteurs principaux: Fan, Liancheng, Dong, Baijun, Chi, Chenfei, Wang, Yanqing, Gong, Yiming, Sha, Jianjun, Pan, Jiahua, Shangguan, Xun, Huang, Yiran, Zhou, Lixin, Xue, Wei
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6276197/
https://ncbi.nlm.nih.gov/pubmed/30509237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-018-0416-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires